Waters Corporation has received US FDA 510(k) clearance for the BD BACTEC FXI Culture System, enabling commercialisation of the automated blood culture platform in the United States.

The clearance addresses a critical diagnostic need in bloodstream infections and sepsis, where earlier detection can support faster clinical decision-making and targeted antimicrobial therapy. Delays in sepsis treatment are associated with higher mortality risk, making laboratory turnaround time an important operational and clinical priority.

The BD BACTEC FXI Culture System is designed for high-throughput microbiology laboratories and automates vial loading, unloading, incubation and detection alerts. Clinical study data showed that the system reduced mean time to detection by approximately three hours, or around 15 percent, compared with the previous-generation BD BACTEC FX Blood Culture System.

The system also includes automated gravimetric measurement of individual blood culture vial volume, intended to reduce pre-analytical variability and support more consistent diagnostics. It provides up to 60-vial automated loading at a time, with available 480- and 960-vial configurations, increasing walk-away time for laboratory staff.

For hospitals and laboratories, adoption will depend on workflow integration, capital planning, throughput needs and the ability to demonstrate clinical and operational value in routine microbiology settings. The system has also received CE Mark under the European Union’s IVDR and PMDA licensing in Japan, supporting broader global market relevance.

As antimicrobial resistance and sepsis pressures increase, automated blood culture systems that improve speed, consistency and scalability are likely to remain central to diagnostic laboratory modernisation.